Table 5:
Post Ibr Therapy | del(17p13) present | Age <65 years |
---|---|---|
Alternate KI | 2 (9%) | 2 (10%) |
Anti-CD20 antibody | 7 (32%) | 4 (19%) |
BR or FCR | 3 (14%) | |
Anthracycline-based regimen | 3 (14%) | 1 (5%) |
Venetoclax | 5 (23%) | 5 (24%) |
SCT / CAR-T | 2 (9%) | 4 (19%) |
Other | 1 (4.5%) | 2 (10%) |